ID   KC1E_HUMAN              Reviewed;         416 AA.
AC   P49674;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Casein kinase I isoform epsilon;
DE            Short=CKI-epsilon;
DE            Short=CKIe;
DE            EC=2.7.11.1;
GN   Name=CSNK1E;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=7797465; DOI=10.1074/jbc.270.25.14875;
RA   Fish K.J., Cegielska A., Getman M.E., Landes G.M., Virshup D.M.;
RT   "Isolation and characterization of human casein kinase I epsilon
RT   (CKI), a novel member of the CKI gene family.";
RL   J. Biol. Chem. 270:14875-14883(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Ono K., Murata-Hori M., Hosoya H.;
RT   "Casein kinase I epsilon from HeLa cell.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH SOCS3, INDUCTION, AND
RP   FUNCTION.
RC   TISSUE=Hematopoietic stem cell;
RX   PubMed=15070676; DOI=10.1182/blood-2003-08-2768;
RA   Okamura A., Iwata N., Nagata A., Tamekane A., Shimoyama M., Gomyo H.,
RA   Yakushijin K., Urahama N., Hamaguchi M., Fukui C., Chihara K., Ito M.,
RA   Matsui T.;
RT   "Involvement of casein kinase Iepsilon in cytokine-induced
RT   granulocytic differentiation.";
RL   Blood 103:2997-3004(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH PER1.
RX   PubMed=10790862; DOI=10.1097/00001756-200004070-00011;
RA   Keesler G.A., Camacho F., Guo Y., Virshup D., Mondadori C., Yao Z.;
RT   "Phosphorylation and destabilization of human period I clock protein
RT   by human casein kinase I epsilon.";
RL   NeuroReport 11:951-955(2000).
RN   [8]
RP   ROLE IN WNT SIGNALING.
RX   PubMed=12556519; DOI=10.1074/jbc.M213265200;
RA   Hino S., Michiue T., Asashima M., Kikuchi A.;
RT   "Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and
RT   is essential for Wnt-3a-induced accumulation of beta-catenin.";
RL   J. Biol. Chem. 278:14066-14073(2003).
RN   [9]
RP   FUNCTION AS PER1 KINASE.
RX   PubMed=15917222; DOI=10.1074/jbc.M502862200;
RA   Shirogane T., Jin J., Ang X.L., Harper J.W.;
RT   "SCFbeta-TRCP controls clock-dependent transcription via casein kinase
RT   1-dependent degradation of the mammalian period-1 (Per1) protein.";
RL   J. Biol. Chem. 280:26863-26872(2005).
RN   [10]
RP   INTERACTION WITH DBNDD2.
RX   PubMed=16618118; DOI=10.1021/bi052354e;
RA   Yin H., Laguna K.A., Li G., Kuret J.;
RT   "Dysbindin structural homologue CK1BP is an isoform-selective binding
RT   partner of human casein kinase-1.";
RL   Biochemistry 45:5297-5308(2006).
RN   [11]
RP   INTERACTION WITH LRP5 AND LRP6.
RX   PubMed=16513652; DOI=10.1074/jbc.M510580200;
RA   Swiatek W., Kang H., Garcia B.A., Shabanowitz J., Coombs G.S.,
RA   Hunt D.F., Virshup D.M.;
RT   "Negative regulation of LRP6 function by casein kinase I epsilon
RT   phosphorylation.";
RL   J. Biol. Chem. 281:12233-12241(2006).
RN   [12]
RP   FUNCTION, AUTOPHOSPHORYLATION, DEPHOSPHORYLATION BY PPP5C, AND ENZYME
RP   REGULATION.
RX   PubMed=16790549; DOI=10.1073/pnas.0604138103;
RA   Partch C.L., Shields K.F., Thompson C.L., Selby C.P., Sancar A.;
RT   "Posttranslational regulation of the mammalian circadian clock by
RT   cryptochrome and protein phosphatase 5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10467-10472(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343; SER-354; THR-362
RP   AND SER-363, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343 AND SER-354, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   INTERACTION WITH SNAI1.
RX   PubMed=20305697; DOI=10.1038/onc.2010.77;
RA   Xu Y., Lee S.H., Kim H.S., Kim N.H., Piao S., Park S.H., Jung Y.S.,
RA   Yook J.I., Park B.J., Ha N.C.;
RT   "Role of CK1 in GSK3beta-mediated phosphorylation and degradation of
RT   snail.";
RL   Oncogene 29:3124-3133(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389; SER-405 AND
RP   SER-408, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.74 ANGSTROMS) OF 1-294 ALONE AND IN COMPLEX
RP   WITH INHIBITOR.
RX   PubMed=23106386; DOI=10.1021/jm301336n;
RA   Long A.M., Zhao H., Huang X.;
RT   "Structural basis for the potent and selective inhibition of casein
RT   kinase 1 epsilon.";
RL   J. Med. Chem. 55:10307-10311(2012).
RN   [24]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-256 AND ARG-413.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Casein kinases are operationally defined by their
CC       preferential utilization of acidic proteins such as caseins as
CC       substrates. Can phosphorylate a large number of proteins.
CC       Participates in Wnt signaling. Phosphorylates DVL1. Central
CC       component of the circadian clock. In balance with PP1, determines
CC       the circadian period length, through the regulation of the speed
CC       and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1
CC       and PER2 nuclear transport and degradation. Inhibits cytokine-
CC       induced granuloytic differentiation. {ECO:0000269|PubMed:12556519,
CC       ECO:0000269|PubMed:15070676, ECO:0000269|PubMed:15917222,
CC       ECO:0000269|PubMed:16790549}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Phosphorylation leads to a decrease of the
CC       catalytic activity. {ECO:0000269|PubMed:16790549}.
CC   -!- SUBUNIT: Monomer. Component of the circadian core oscillator,
CC       which includes the CRY proteins, CLOCK, or NPAS2, ARTNL/BMAL1 or
CC       ARTNL2/BMAL2, CSNK1D and/or CSNK1E, TIMELESS and the PER proteins.
CC       Interacts with ANKRD6, DBNDD2, LRP5, LRP6 and SOCS3. Interacts
CC       with SNAI1 (via zinc fingers). {ECO:0000269|PubMed:10790862,
CC       ECO:0000269|PubMed:15070676, ECO:0000269|PubMed:16513652,
CC       ECO:0000269|PubMed:16618118, ECO:0000269|PubMed:20305697,
CC       ECO:0000269|PubMed:23106386}.
CC   -!- INTERACTION:
CC       P25054:APC; NbExp=8; IntAct=EBI-749343, EBI-727707;
CC       O15169:AXIN1; NbExp=5; IntAct=EBI-749343, EBI-710484;
CC       O70239:Axin1 (xeno); NbExp=7; IntAct=EBI-749343, EBI-6857773;
CC       O14640:DVL1; NbExp=6; IntAct=EBI-749343, EBI-723489;
CC       Q60838:Dvl2 (xeno); NbExp=3; IntAct=EBI-749343, EBI-641940;
CC       Q92997:DVL3; NbExp=8; IntAct=EBI-749343, EBI-739789;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-749343, EBI-352572;
CC       P23508:MCC; NbExp=3; IntAct=EBI-749343, EBI-307531;
CC       Q00987:MDM2; NbExp=3; IntAct=EBI-749343, EBI-389668;
CC       Q16625:OCLN; NbExp=7; IntAct=EBI-749343, EBI-2903088;
CC       O15055:PER2; NbExp=3; IntAct=EBI-749343, EBI-1054296;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined, including
CC       brain, heart, lung, liver, pancreas, kidney, placenta and skeletal
CC       muscle. Expressed in monocytes and lymphocytes but not in
CC       granulocytes.
CC   -!- INDUCTION: Down-regulated during granulocytic differentiation.
CC       {ECO:0000269|PubMed:15070676}.
CC   -!- PTM: Autophosphorylated. Partially dephosphorylated by PPP5C. May
CC       be dephosphorylated by PP1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. Casein kinase I subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L37043; AAC41761.1; -; mRNA.
DR   EMBL; AB024597; BAA92345.1; -; mRNA.
DR   EMBL; AB091043; BAC10902.1; -; mRNA.
DR   EMBL; CR456429; CAG30315.1; -; mRNA.
DR   EMBL; AL020993; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006490; AAH06490.1; -; mRNA.
DR   CCDS; CCDS13970.1; -.
DR   PIR; I61744; I61744.
DR   RefSeq; NP_001276841.1; NM_001289912.1.
DR   RefSeq; NP_001885.1; NM_001894.4.
DR   RefSeq; NP_689407.1; NM_152221.2.
DR   UniGene; Hs.474833; -.
DR   UniGene; Hs.720223; -.
DR   PDB; 4HNI; X-ray; 2.74 A; A/B=1-294.
DR   PDB; 4HOK; X-ray; 2.77 A; A/C/E/G/I/K/M/O/Q/S/U/W=1-294.
DR   PDBsum; 4HNI; -.
DR   PDBsum; 4HOK; -.
DR   ProteinModelPortal; P49674; -.
DR   SMR; P49674; -.
DR   BioGrid; 107838; 173.
DR   DIP; DIP-38050N; -.
DR   IntAct; P49674; 111.
DR   MINT; MINT-1444044; -.
DR   STRING; 9606.ENSP00000352929; -.
DR   BindingDB; P49674; -.
DR   ChEMBL; CHEMBL4937; -.
DR   GuidetoPHARMACOLOGY; 1998; -.
DR   iPTMnet; P49674; -.
DR   PhosphoSitePlus; P49674; -.
DR   BioMuta; CSNK1E; -.
DR   DMDM; 1346369; -.
DR   EPD; P49674; -.
DR   PaxDb; P49674; -.
DR   PeptideAtlas; P49674; -.
DR   PRIDE; P49674; -.
DR   DNASU; 1454; -.
DR   Ensembl; ENST00000359867; ENSP00000352929; ENSG00000213923.
DR   Ensembl; ENST00000396832; ENSP00000380044; ENSG00000213923.
DR   Ensembl; ENST00000400206; ENSP00000383067; ENSG00000213923.
DR   Ensembl; ENST00000403904; ENSP00000384074; ENSG00000213923.
DR   GeneID; 102800317; -.
DR   GeneID; 1454; -.
DR   KEGG; hsa:102800317; -.
DR   KEGG; hsa:1454; -.
DR   CTD; 102800317; -.
DR   CTD; 1454; -.
DR   DisGeNET; 1454; -.
DR   GeneCards; CSNK1E; -.
DR   GeneCards; LOC400927-CSNK1E; -.
DR   H-InvDB; HIX0080286; -.
DR   HGNC; HGNC:2453; CSNK1E.
DR   HPA; CAB009626; -.
DR   HPA; HPA026288; -.
DR   MIM; 600863; gene.
DR   neXtProt; NX_P49674; -.
DR   OpenTargets; ENSG00000213923; -.
DR   PharmGKB; PA26953; -.
DR   eggNOG; KOG1164; Eukaryota.
DR   eggNOG; ENOG410XPGP; LUCA.
DR   GeneTree; ENSGT00760000119040; -.
DR   HOGENOM; HOG000182055; -.
DR   HOVERGEN; HBG000176; -.
DR   InParanoid; P49674; -.
DR   KO; K08960; -.
DR   OrthoDB; EOG091G0AFG; -.
DR   PhylomeDB; P49674; -.
DR   TreeFam; TF300544; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-201688; WNT mediated activation of DVL.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SABIO-RK; P49674; -.
DR   SignaLink; P49674; -.
DR   SIGNOR; P49674; -.
DR   ChiTaRS; CSNK1E; human.
DR   GeneWiki; CSNK1E; -.
DR   PRO; PR:P49674; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000213923; -.
DR   CleanEx; HS_CSNK1E; -.
DR   ExpressionAtlas; P49674; baseline and differential.
DR   Genevisible; P49674; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0030529; C:intracellular ribonucleoprotein complex; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0034613; P:cellular protein localization; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0097711; P:ciliary basal body docking; TAS:Reactome.
DR   GO; GO:0048512; P:circadian behavior; IEA:Ensembl.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006897; P:endocytosis; IBA:GO_Central.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1902004; P:positive regulation of beta-amyloid formation; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; IC:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:1905426; P:positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   GO; GO:1903827; P:regulation of cellular protein localization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0006364; P:rRNA processing; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016055; P:Wnt signaling pathway; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Biological rhythms; Complete proteome;
KW   Cytoplasm; Kinase; Methylation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    416       Casein kinase I isoform epsilon.
FT                                /FTId=PRO_0000192837.
FT   DOMAIN        9    277       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      15     23       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    128    128       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      38     38       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     343    343       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     354    354       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     362    362       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     382    382       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q9JMK2}.
FT   MOD_RES     389    389       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     405    405       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     408    408       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     256    256       R -> L (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042082.
FT   VARIANT     413    413       H -> R (in dbSNP:rs35665927).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042083.
FT   TURN          6      8       {ECO:0000244|PDB:4HNI}.
FT   STRAND       14     16       {ECO:0000244|PDB:4HNI}.
FT   STRAND       22     28       {ECO:0000244|PDB:4HNI}.
FT   TURN         29     31       {ECO:0000244|PDB:4HNI}.
FT   STRAND       35     41       {ECO:0000244|PDB:4HNI}.
FT   HELIX        51     56       {ECO:0000244|PDB:4HNI}.
FT   TURN         57     61       {ECO:0000244|PDB:4HNI}.
FT   STRAND       68     74       {ECO:0000244|PDB:4HNI}.
FT   STRAND       77     83       {ECO:0000244|PDB:4HNI}.
FT   HELIX        89     95       {ECO:0000244|PDB:4HNI}.
FT   TURN         96     98       {ECO:0000244|PDB:4HNI}.
FT   HELIX       102    120       {ECO:0000244|PDB:4HNI}.
FT   TURN        121    123       {ECO:0000244|PDB:4HNI}.
FT   HELIX       131    133       {ECO:0000244|PDB:4HNI}.
FT   STRAND      134    136       {ECO:0000244|PDB:4HNI}.
FT   HELIX       139    141       {ECO:0000244|PDB:4HNI}.
FT   STRAND      145    147       {ECO:0000244|PDB:4HNI}.
FT   STRAND      154    157       {ECO:0000244|PDB:4HNI}.
FT   TURN        159    161       {ECO:0000244|PDB:4HNI}.
FT   HELIX       177    179       {ECO:0000244|PDB:4HNI}.
FT   HELIX       182    185       {ECO:0000244|PDB:4HNI}.
FT   HELIX       192    208       {ECO:0000244|PDB:4HNI}.
FT   TURN        212    215       {ECO:0000244|PDB:4HOK}.
FT   HELIX       221    234       {ECO:0000244|PDB:4HNI}.
FT   HELIX       237    240       {ECO:0000244|PDB:4HNI}.
FT   TURN        241    243       {ECO:0000244|PDB:4HNI}.
FT   HELIX       246    255       {ECO:0000244|PDB:4HNI}.
FT   HELIX       266    280       {ECO:0000244|PDB:4HNI}.
FT   HELIX       289    291       {ECO:0000244|PDB:4HNI}.
SQ   SEQUENCE   416 AA;  47315 MW;  EE1B1698AE914324 CRC64;
     MELRVGNKYR LGRKIGSGSF GDIYLGANIA SGEEVAIKLE CVKTKHPQLH IESKFYKMMQ
     GGVGIPSIKW CGAEGDYNVM VMELLGPSLE DLFNFCSRKF SLKTVLLLAD QMISRIEYIH
     SKNFIHRDVK PDNFLMGLGK KGNLVYIIDF GLAKKYRDAR THQHIPYREN KNLTGTARYA
     SINTHLGIEQ SRRDDLESLG YVLMYFNLGS LPWQGLKAAT KRQKYERISE KKMSTPIEVL
     CKGYPSEFST YLNFCRSLRF DDKPDYSYLR QLFRNLFHRQ GFSYDYVFDW NMLKFGAARN
     PEDVDRERRE HEREERMGQL RGSATRALPP GPPTGATANR LRSAAEPVAS TPASRIQPAG
     NTSPRAISRV DRERKVSMRL HRGAPANVSS SDLTGRQEVS RIPASQTSVP FDHLGK
//
